http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021041923-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1543b2b19ec0e331a0dcd89888cbef5f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-18 |
| filingDate | 2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2add0cba4273ae23a2ed02ccfa85689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d0ceafabe9b4d1c7ede718ed0dc8c59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eae1d1a1e39f1e7fc0a36107e313e70 |
| publicationDate | 2021-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021041923-A1 |
| titleOfInvention | Transmission prevention of viruses with application of antiseptic composition |
| abstract | Aspects of the present disclosure relate to a method of preventing transmission of an enveloped RNA virus. The method includes applying to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan. The first mammalian subject not substantially colonized by the enveloped RNA virus interacts with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction, the second viral load is no greater than 0.5 log increase over an initial viral load over a duration of the treatment plan. The mucosal tissue is in the nasopharynx, nasal cavity, or anterior nares of the mammalian subject. The antiseptic composition comprises iodine, iodophor, or combinations thereof. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023161762-A1 |
| priorityDate | 2019-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 264.